# Pharmacokinetic Comparison Of All FK-506 Formulations

> **NCT02339246** · PHASE3 · COMPLETED · sponsor: **Veloxis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Renal Failure

## Interventions

- **DRUG:** Prograf vs Envarsus XR vs Astagraf XL
- **DRUG:** Prograf vs Astagraf XL vs Envarsus XR

## Key facts

- **NCT ID:** NCT02339246
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339246, "Pharmacokinetic Comparison Of All FK-506 Formulations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02339246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*